Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects

Journal of Clinical Pharmacology

Volumn 48, Issue 2, 2008, Pages 246-252

  Lefèvre, Gilbert ^a   Pommier, Françoise ^b   Sȩdek, Greg ^a   Allison, Mark ^c   Huang, Hsun Lun Aaron ^a   Kiese, Beate ^a   Ho, Yu Yun ^a   Appel Dingemanse, Silke ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS PHARMA K K   (Japan)

^c MDS Inc   (Canada)

Author keywords

Alzheimer's disease; Exelon; Pharmacokinetics; Rivastigmine; Transdermal patch

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; AREA UNDER CURVE; BENZYLAMINES; BIOLOGICAL AVAILABILITY; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIZZINESS; FEMALE; HALF-LIFE; HEADACHE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; PHENOLS; PHENYLCARBAMATES; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOLUTIONS; TANDEM MASS SPECTROMETRY; VOMITING;

EID: 38349084191     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007312154     Document Type: Article

References (32)

1. Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. CMAJ. 2002 ; 166: 616-623.
2. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. Beta-amyloid (1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Bio Chem. 2000 ; 2075: 5626-5632.
3. Alzheimer's disease: risk stratification, patient evaluation, and outcome-effective pharmacologic therapy-year 2004 clinical update. Available at http://www.ahcpub.com. Accessed July 16, 2007.
4. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry. 1997 ; 154: 1-39.
5. Cummings JL, Frank JC, Cherry D., et al. Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician. 2002 ; 65: 2263-2272.
6. Cummings JL, Frank JC, Cherry D., et al. Guidelines for managing Alzheimer's disease: part II. Treatment. Am Fam Physician. 2002 ; 65: 2525-2534.
7. Doody RS, Stevens JC, Beck RN, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 ; 56: 115411166.
8. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997 ; 278: 1363-1371.
9. Farlow M., Anand R., Messina J. Jr, Hartman R., Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000 ; 44: 236-241.
10. Karaman Y., Erdogan F., Koseoglu E., Turan T., Ozdemir Ersoy A. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005 ; 19: 51-56.
11. Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ. 1999 ; 318: 633-638.
12. Ballard CG Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol. 2002 ; 47: 64-70.
13. Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract. 2002 ; 56: 206-214.
14. Grossberg GT, Stähelin HB, Messina JC, Anand R., Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and 22 classes of medications. Int J Geriat Psychiatry. 2000 ; 15: 242-247.
15. Polinsky RJ Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 ; 20: 634-647.
16. Imbimbo BP Pharmacodynamic tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs. 2001 ; 15: 375-390.
17. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. World Medical Association, 2004. Available at http://www.wma.net/e/policy/b3. htm. Accessed July 16, 2007.
18. Anon. Guideline for Good Clinical Practice: ICH Harmonised Tripartite Guideline. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at http://www.ich.org/LOB/media/MEDIA482.pdf. Accessed July 16, 2007.
19. Pommier F., Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B. 2003 ; 784: 301-313.
20. Ellmann GL, Courtney KD, Andres V., Featherstone RM A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 ; 7: 88-90.
21. Sramek JJ, Anand R., Wardle TS, Irwin P., Hartman RD, Culter NR Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci. 1996 ; 58: 1201-1207.
22. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging. 1998 ; 13: 391-411.
23. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand. 1998 ; 97: 244-250.
24. Kennedy JS, Polinsky RJ, Johnson B., et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol. 1999 ; 19: 513-521.
25. Jann MW Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacother. 2000 ; 20: 1-12.
26. Hossain M., Jhee SS, Shiovitz T., et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet. 2002 ; 41: 225-234.
27. Jann MW, Shirley KL, Small GW Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002: 41: 719-739.
28. Williams BR, Nazarians A., Gill MA A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther. 2003 ; 25: 1634-1653.
29. Lee L., Hossain M., Wang Y., Sedek G. Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. J Clin Pharmacol. 2004 ; 44: 599-604.
30. Lefèvre G., Sȩdek G., Jhee SJ, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients [published online ahead of print May 23, 2007]. Clin Pharm Ther. doi:10.1038/sj.clpt.6100242.
31. Winblad B., Cummings J., Andreasen N., et al. A 6-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007 ; 22: 456-467.
32. Winblad B., Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007 ; 22: 485-491.